AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04408742 — intervention group
Intervention type: OTHER
Intervention: dual task performance
Description: The timed up and go test (TUG) was used in the evaluation of dual task performance. For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. TUG test was performed initially without task, and then with cognitive and motor tasks, respectively. Cognitive task given during the test is counting three backwards from 100 or counting the names starting with the letter A, and motor task given is to carry three glasses of water on a tray. The time elapses between standing up from the chair and sitting back to chair was recorded as the test result. As time increases, dual task performance decreases.
Study NCT06041542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 10-second hand grip and release test
Description: To grip and release hand in ten seconds
Study NCT02659280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjunct Therapy
Description: Store and Forward Tele-heath
Study NCT02659280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Outpatient Physical Therapy
Study NCT04541953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation Therapy
Description: Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises and stretching.
Study NCT04541953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person Rehabilitation Therapy
Description: Range of motion exercises and stretching
Study NCT04459000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STARS + maternal Attachment Biobehavioral Catchup home visiting model
Description: Mothers receive up to 12 home visits from a licensed therapist focused on attachment and positive parenting in substance exposed babies. This includes 1 prenatal home visit and up to 11 postnatal visits.
Study NCT04459000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STARs Only
Description: Participants receive prenatal care in the STAR clinic (a clinic specifically designed to support mothers with substance abuse who are at risk of losing their children to child welfare at birth).
Study NCT04439227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT04284592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic post-conditioning (RIP)
Description: The limb RIP was applied after leaving of cardiopulmonary bypass and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on an arm and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff.
Study NCT00711555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant, ondansetron, dexamethasone
Description: On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting.
Study NCT03655470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning
Description: Safety planning is an individual coping intervention to reduce suicidal risk in adolescents
Study NCT03655470 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care entails sending an adolescent for an emergency evaluation for suicidal risk in an Emergency Department
Study NCT03840395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngeal Electrical Stimulation (PES)
Description: The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.
Study NCT03840395 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pharyngeal Electrical Stimulation (PES)
Description: The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.
Study NCT02098213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate spa treatment
Description: soon after randomization: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all participating of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
Study NCT02098213 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Late Spa treatment
Description: soon after 4,5 months visit: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
Study NCT00638235 — intervention group
Intervention type: DEVICE
Intervention: AMS Apogee™ with IntePro
Description: Mesh implant for posterior wall pelvic organ prolapse
Study NCT04232917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LPAPI®
Description: Treatment
Study NCT04232917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00991094 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires
Study NCT00991094 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT00638235 — intervention group
Intervention type: DEVICE
Intervention: AMS Apogee™ with Intexen LP
Description: Graft implant for posterior wall pelvic organ prolapse
Study NCT00638235 — intervention group
Intervention type: DEVICE
Intervention: AMS Perigee™ with IntePro
Description: Mesh implant for anterior wall pelvic organ prolapse
Study NCT00638235 — intervention group
Intervention type: DEVICE
Intervention: AMS Perigee™ with IntePro Lite
Description: Mesh implant for anterior wall pelvic organ prolapse
Study NCT00638235 — intervention group
Intervention type: DEVICE
Intervention: AMS Apogee™ with IntePro Lite
Description: Mesh implant for posterior wall pelvic organ prolapse
Study NCT00638235 — intervention group
Intervention type: DEVICE
Intervention: AMS Elevate™ Apical & Posteiror with IntePro Lite
Description: Mesh implant for apical and posterior wall pelvic organ prolapse
Study NCT00638235 — intervention group
Intervention type: DEVICE
Intervention: AMS Elevate™ Apical & Posteiror with IntXen LP
Description: Graft implant for apical and posterior wall pelvic organ prolapse
Study NCT00638235 — intervention group
Intervention type: DEVICE
Intervention: AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)
Description: Mesh implant for anteiror and apical wall pelvic organ prolapse
Study NCT00638235 — intervention group
Intervention type: DEVICE
Intervention: AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)
Description: Mesh implant for anteiror and apical wall pelvic organ prolapse
Study NCT02905383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A multi-component exercise program that consists of endurance training, progressive strength exercises and balance exercises.
Study NCT03759015 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health education
Description: All subjects are tasked to create an original 10-minute theater about physical activity and diet/nutrition.
Study NCT03635437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Aminobutyric Acid (GABA)
Description: Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
Study NCT02218099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8232
Description: Oral
Study NCT04343586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue light phototherapy
Description: Phototherapy- Wavelength: 417±15 nm
Study NCT02849275 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Free 1% Milk
Description: isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
Study NCT02849275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic Treatment
Description: Probiotic treatment, consumed once daily, over 4-5 weeks.
Study NCT05030402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maitland
Description: An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
Study NCT05030402 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tens, exercise, SW
Description: An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
Study NCT05030402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tens, exercise, SW
Description: An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
Study NCT05030402 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
Study NCT03635437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
Study NCT00466622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
Study NCT00466622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 tablets x 2 daily. Orally from Weifa
Study NCT01676883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioelectric impedance
Description: removal of calluses and corns by pedicure
Study NCT01676883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography
Study NCT02218099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study NCT04529642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inertial Measurement Unit evaluation
Description: An IMU was worn by the subjects during the execution of the 6MWT, to assess the kinematic parameters of gait.
Study NCT02185781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous NK cells infusions
Description: Each patient will receive repeated intravenous (IV) infusions of escalating doses of expanded autologous NK cells.~The initial dose will be 1 x 106/kg of recipient body weight (BW), followed by half log increments of the dose level for each infusion, to a maximum of 1 x 108/kg of recipient BW or until they experience any toxicity, for a maximum of 5 infusions. The minimum interval between each infusion will be 28 days. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive TKI maintenance.
Study NCT04810923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: i-PRF
Description: intra-articular i-PRF injection after arthrocentesis
Study NCT04810923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Description: Arthrocentesis procedure with 2 to 3 mL saline solution to lavage the superior compartment of temporomandibular joint.
Study NCT02940743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education (Edu)
Description: This intervention will take place during weeks 1-4 at the dialysis center. Each week, study staff will present participants with a brief educational video on: phosphorus binder adherence (week 1), meeting dietary protein needs (week 2), restricting dietary sources of phosphorus (week 3), and eliminating phosphorus-based food additives (week 4). These videos will be loaded onto tablet (Personal Computers) PCs so that participants can easily view them during regular dialysis treatment.
Study NCT02940743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SM intervention
Description: During the first 12 weeks of the intervention, a study dietitian will review the participants' records, and provide individualized feedback via a password-protected NYULMC email address. Feedback will be provided twice per week during weeks 1-4, once per week during weeks 5-8, and once every two weeks during weeks 9-12. The email messages will focus on both the importance of self-monitoring and the behavioral targets of the intervention. Feedback will use standardized language rather than specific dietary examples to avoid providing individualized counseling to participants (which is not the purpose of the SM intervention).
Study NCT02881320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Adult Strength)
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food.
Study NCT02881320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Low Dose)
Description: 30/120/15 mg FDC tablets administered orally once daily without regard to food.
Study NCT02881320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 2 x B/F/TAF 15/60/7.5 mg (total daily dose 30/120/15 mg) FDC tablets administered orally as TOS, once daily.
Study NCT02881320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 2 x B/F/TAF 3.75/15/1.88 mg (total daily dose 15/60/7.52 mg) FDC tablets administered orally as TOS, twice daily.
Study NCT02940743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognitive Therapy (SCT)
Description: This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.
Study NCT02197533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written List
Description: Written list of seven management strategies for OAB to be produced during verbal discussion about management.
Study NCT02881320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 1 x B/F/TAF 3.75/15/1.88 mg (total daily dose 7.5/30/3.76 mg) FDC tablets administered orally as TOS, twice daily.
Study NCT01775215 — intervention group
Intervention type: RADIATION
Intervention: Cardiac I123-MIBG Scintigraphy
Study NCT01775215 — intervention group
Intervention type: OTHER
Intervention: Cardiac MRI
Study NCT01775215 — intervention group
Intervention type: OTHER
Intervention: Stress and rest Echocardiogram
Study NCT01775215 — intervention group
Intervention type: OTHER
Intervention: High Sensitivity Troponin I
Study NCT01775215 — intervention group
Intervention type: OTHER
Intervention: Brain Natriuretic Peptide
Study NCT02881320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (TOS)
Description: 1 x B/F/TAF 1.88/7.5/0.94 mg (total daily dose 3.76/15/1.88 mg) FDC tablets administered orally as TOS, twice daily
Study NCT02555787 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: oral
Study NCT04469881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR
Description: Participants will be asked to do the following things:~1. Wear VR goggles for the duration of the surgery~2. Answer questions about their experience with the VR goggles~3. Give permission for the researchers to collect information about the anesthesia medications used, pain medications used, and reported pain scores during the surgery and during recovery in the hospital
Study NCT01241695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement, food for special medical purposes
Description: 2 servings of 200 ml per day, treatment period: 12 weeks
Study NCT01241695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral nutritional supplement, food for special medical purposes
Description: 2 servings of 200 ml per day, treatment period: 12 weeks
Study NCT01944202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational and feedback intervention, as described in the Arm Description.
Study NCT00817557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol
Description: Anti-inflammatory
Study NCT00817557 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rewetter
Study NCT02247440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon + ribavirin under HIV physician supervision
Description: Peg-interferon + ribavirin under HIV physician supervision
Study NCT02181582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapunil
Description: Single peroral administration
Study NCT02181582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Description: Positron emission tomography, which creates images by detecting radioactivity.
Study NCT02655991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Case Monitoring
Description: Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.
Study NCT02655991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
Study NCT02655991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
Study NCT02014493 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannulae (HFNC)
Description: HFNC 6 l/pr.min
Study NCT02014493 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP 6 l/pr.min
Study NCT01054274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: novel stent
Description: Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
Study NCT01054274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional covered stent
Description: Patients undergo placement of a conventional covered stent on day 1.
Study NCT02005692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynaSense sensor